Weight gain: Side effect of atypical neuroleptics?

Journal of Clinical Psychopharmacology

Volumn 19, Issue 4, 1999, Pages 316-321

  Wetterling, Tilman ^a,b   Müßigbrodt, Heidi E ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; RISPERIDONE; SULPIRIDE; ZOTEPINE;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; DELUSION; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHIZOIDISM; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; CLOZAPINE; DELUSIONS; DIBENZOTHIEPINS; FEMALE; HUMANS; LONG-TERM CARE; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; RISPERIDONE; SCHIZOPHRENIA; SULPIRIDE; WEIGHT GAIN;

EID: 0344348977     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199908000-00006     Document Type: Article

References (37)

1. Kinon BJ, Lieberman JA. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology (Berl) 1996;124:2-34.
2. Schotte A, Janssen PFM, Gommeren W, Luyten WHML, Van Gompel P, Lesage AS, De Loore K, Leysen JE. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996;124: 57-73.
3. Bustillo JR, Buchanan RW, Irish D, Breier A. Differential effect of clozapine on weight: a controlled study. Am J Psychiatry 1996; 153:817-9.
4. Cohen S, Chiles J, MacNaughton A. Weight gain associated with clozapine. Am J Psychiatry 1990;147:503-4.
5. Hummer M, Kemmler G, Kurz M, Kurzthaler I, Oberbauer H, Fleischhacker WW. Weight gain induced by clozapine. Eur Neuropsychopharmacol 1995;5:437-40.
6. Lamperti JS, Bellnier T, Schwarzkopf SB. Weight gain among schizophrenic patients treated with clozapine. Am J Psychiatry 1992;149:689-90.
7. Leadbetter R, Shutty M, Pavalonis D, Vieweg V, Higgins P, Downs M. Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 1992;149:68-72.
8. Umbricht DS, Pollack S, Kane JM. Clozapine and weight gain. J Clin Psychiatry 1994;55[suppl B]:157-60.
9. Rey M-J, Schulz P, Costa C, Dick P, Tissot R. Guidelines for the dosage of neuroleptics. I: Chlorpromazine equivalents of orally administered neuroleptics. Int Clin Psychopharmacol 1989;4: 95-104.
10. National Institute of Mental Health Clinical Global Impressions (CGI). In: Guy W, ed. ECDEU assessment manual for psychopharmacology, revised edition. Rockville (MD): U.S. Dept. of Health, Education, and Welfare, 1970:217-22.
11. Bernstein JG. Induction of obesity by psychotropic drugs. Ann N Y Acad Sci 1987;499:203-15.
12. Silverstone T, Smith G, Goodall E. Prevalence of obesity in patients receiving depot antipsychotics. Br J Psychiatry 1988;153: 214-7.
13. McCreadie RG, Todd N, Livingston M, Eccleson D, Watt JAG, Herrington RN, Tait D, Crocket G, Mitchell MJ, Huitfeld B. A double-blind comparative study of remoxipride and thioridazine in the acute phase of schizophrenia. Acta Psychiatr Scand Suppl 1990;358:136-7.
14. Falloon I, Watt D, Shephard M. Pimozide and fluphenazine decanoate in continuation therapy. Psychol Med 1978;8:59-70.
15. Marriott P, Pansa M, Hiep A. Depot fluphenazine maintenance treatment and associated weight changes. Compr Psychiatry 1981;22:320-5.
16. Amidsen A. Drug produced obesity: experiences with chlorpromazine, perphenazine and clopenthixol. Dan Med Bull 1964; 11:182-9.
17. Harris E, Eth S. Weight gain during neuroleptic treatment. Int J Nurs Stud 1981;18:171-6.
18. Johnson DA, Breen M. Weight changes with depot neuroleptic maintenance therapy. Acta Psychiatr Scand 1979;59:525-8.
19. Chouinard G, Annable L, Kropsky M. A double-blind controlled study of pipothiazine palmitate in the maintenance treatment of schizophrenic outpatients. J Clin Pharmacol 1978;18:148-54.
20. Stanton JM. Weight gain associated with neuroleptic medication: a review. Schizophr Bull 1995;21:463-72.
21. Höyberg OJ, Fensbo C, Renwig J, Lingjaerde O, Sloth-Nielsen M, Salvesen I. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand 1993;88:395-402.
22. Song F. Risperidone in the treatment of schizophrenia: a metaanalysis of randomized controlled trials. J Psychopharmacol 1997;11:65-71.
23. Claus A, Bollen J, De-Cuyper H, Enenian M, Malfroid M, Peuskens J, Heylen S. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992;85:295-305.
24. Klieser E, Lehmann E, Kinzler E, Wurthmann C, Heinrich K. Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol 1995;15[suppl 1]:45S-51S.
25. Findling RL, Maxwell K, Wiznitzer M. An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacol Bull 1997;33:155-9.
26. McDougle CJ, Holmes JP, Bronson MR, Anderson GM, Volkmar FR, Price LH, Cohen DJ. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry 1997; 36:685-93.
27. Beasley CM, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 1996;124:159-67.
28. Beasley CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol. Neuropsychopharmacology 1996;14:111-23.
29. Hyttel J, Larsen J-J, Christensen AV, Arnt J. Receptor-binding profiles of neuroleptics. In: Chase DE, Chase TN, Christensen AV, Gerlach J, eds. Dyskinesia: research and treatment. Berlin: Springer-Verlag, 1985:9-18.
30. Blundell JE. Serotonin and appetite. Neuropharmacology 1984; 23:1537-51.
31. Leibowitz SF. The role of serotonin in eating disorders. Drugs 1990;39[suppl 3]:33-48.
32. Wurtman JJ, Wurtman RJ, Growdon JH, Henry P, Lipscomb A, Zeisel S. Carbohydrate craving in obese people: suppression by treatments affecting serotoninergic transmission. Int J Eat Disord 1981;1:2-11.
33. Darga LL, Carroll-Michals L, Botsford SJ, Lucas CP. Fluoxetine's effect on weight loss in obese subjects. Am J Clin Nutr 1991; 54:321-5.
34. Garattini S, Caccia S, Mennini T, Samanin R. Consol S, Ladinski H. Biochemical pharmacology of the anorectic drug fenfluramine: a review. Curr Med Res Opin 1987:1:15-27.
35. Wise SD. Clinical studies with fluoxetine in obesity. Am J Clin Nutr 1992;55:S181-S184.
36. Goodall E, Oxtoby C, Richards R, Watkinson G, Brown D, Silverstone T. A clinical trial of the efficacy and acceptability of d-fenfluramine in the treatment of neuroleptic-induced obesity. Br J Psychiatry 1988;153:208-13.
37. Vestergaard P, Amidsen A, Schou M. Clinically significant sideeffects of lithium treatment: a survey of 237 patients in long-term treatment. Acta Psychiatr Scand 1980;62:193-200.